IP Library Granted Patent US 7,015,234
Granted Patent B2
US 7,015,234 · App. 10/485,905 · Granted Mar 21, 2006

Hydroxamic acid derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,015,234
App. No.
10/485,905
Granted
Mar 21, 2006
Kind
B2
Abstract

Compounds of the general formula (I) are described wherein R 1 and R 2 , which may be the same or different, is each a hydrogen atom or a CF 3 , CF 2 H or CFH 2 group, provided that when one of R 1 and R 2 is a hydrogen atom, then the other is a CF 3 , CF 2 H or CFH 2 group, and the salts, solvates or hydrates thereof. Compounds of the invention are potent MMP inhibitors which advantageously do not cause tendonitis in a relevant animal model. Compounds of the invention may be expected to be of use in medicine, especially where the avoidance of side effects, such as joint pain, is desired.

Claims (10)

1. A compound of formula (I):

wherein:

R 1 and R 2 , which may be the same or different, is each a hydrogen atom or a CF 3 , CF 2 H or CFH 2 group, provided that when one of R 1 or R 2 is a hydrogen atom the other is a CF 3 , CF 2 H or CFH 2 group; and the salts, solvates or hydrates thereof.

2. A compound according to claim 1 , wherein R 1 is a hydrogen atom and R 2 is a CF 3 , CF 2 H or CFH 2 group.

3. A compound according to claim 1 , wherein R 2 is a hydrogen atom and R 1 is a CF 3 , CF 2 H or CFH 2 group.

4. A compound which is 4-[4-(4-trifluoromethylphenoxy)piperidine-1-sulfonylmethyl]tetrahydropyran-4-carboxylic acid hydroxyamide; and the salts, solvates or hydrates thereof.

5. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable diluent or carrier.

6. A compound according to claim 1 for use in the treatment of cancer, inflammation, or an autoimmune, infectious or ocular disease.

7. A compound according to claim 1 for use in the treatment of graft versus host reactions, psoriasis, atopic dermatitis, rhinitis, eczema, systemic lupus erythematosus, solid organ transplant and cystic fibrosis.

8. A compound according to claim 1 , for use in the treatment of rheumatoid arthritis, osteoarthritis, osteoporosis, Crohn's Disease, ulcerative colitis, multiple sclerosis, periodontitis, bone resorption, bacterial infections, epidermolysis bullosa, tumour growth, angiogenesis, ophthalmological disease, retinopathy, asthma, emphysema, bronchitis, and chronic obstructive pulmonary disease (COPD).

Assignments (3)
CON Recorded Sep 4, 2008
From: CELLTECH R&D LIMITED
To: UCB PHARMA S.A.
Reel/Frame 021478/0274 →
CORRECTIVE ASSIGNMENT TO CORRECT SERIAL NUMBER 10495905 NUBMER SHOULD BE 10485905 RECORDED ON REEL 015464 FRAME 0533 Recorded Feb 28, 2005
From: DYKE, HAZEL JOAN; WATSON, ROBERT JOHN
To: CELLTECH R & D LIMITED
Reel/Frame 016292/0773 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2004
From: DYKE, HAZEL JOAN; WATSON, ROBERT JOHN
To: CELLTECH R&D LIMITED
Reel/Frame 015464/0533 →